Brought to you by:
SVS updates patient reading materials to ‘improve accessibility’
The Society for Vascular Surgery (SVS) has revamped the patient flyers on YourVascularHealth.org—the Society’s patient-facing online patient resource—in an effort to lower the reading level of the material and improve accessibility for patients. The site contains five flyers on the most…
Claudication: Medicare-linked data outline higher rates of progression to CLTI after revascularization among Black women
Black women with claudication had the highest rate of progression to chronic limb-threatening ischemia (CLTI) after lower extremity revascularization at 180 days, new data from a Medicare-linked Vascular Quality Initiative (VQI) procedural registry show. The results were demonstrated in a…
New era beckons: Vascular Specialist moves in-house as new chapter opens for SVS official newspaper
Malachi Sheahan III, MD, has been at the helm of Vascular Specialist for more than seven years. In that time, it is fair to say the newspaper—the official voice of the Society for Vascular Surgery (SVS)—has evolved. About a year…
Missing a step? Searching for meaning in claudication research
A team of leading vascular surgeons in the care of patients with PAD weigh up evidence for the treatment of claudication, calling for research focused on clarifying who should be revascularized, and who should continue with medical management and exercise…
Care for intermittent claudication considered ‘inappropriate’ found to be common, putting patients at ‘increased’ risk
In a multi-institutional cohort of patients with intermittent claudication (IC), care deemed inappropriate, or where the risk outweighs the benefit, by the SVS appropriate use criteria (AUC) for the management of IC was “common” and associated with increased risk of…
Meta-analysis: Drug-coated devices show comparable aggregate outcomes to non-drug-coated devices in CLTI
Drug-coated balloon (DCB) angioplasty appears to offer similar benefits as plain old balloon angioplasty (POBA), with or without stenting, for patients with chronic limb-threatening ischemia (CLTI) who are undergoing endovascular femoropopliteal segment lower extremity revascularization, according to new meta-analysis data…
Atherectomy in PAD: Meta-analysis of ‘extensive’ published literature supports use in ‘appropriately selected’ patients
A systematic review and meta-analysis of more than 300 original investigations on atherectomy in peripheral arterial disease (PAD) highlights “overall favorable” clinical outcomes. This and other findings from what researchers say is the first investigation to provide a “comprehensive” overview…
Esprit BTK: Drug-eluting resorbable scaffold poised as first-line therapy for below-the-knee CLTI
This advertorial is sponsored by Abbott. “We now have something on label and FDA [Food and Drug Administration] approved that we can use as a first-line therapy for tibial vessels,” Richard Pin, MD, chief of vascular surgery at Southcoast Health…
‘We need to look at the totality of evidence’: VIVA panelists examine SWEDEPAD findings
A focused session at the 2025 Vascular Interventional Advances (VIVA) conference (2–5 November, Las Vegas, USA) homed in on the latest findings from the SWEDEPAD registry-based randomized controlled trials (RCTs), with panelists discussing the results with reference to the wider…
Cracking CLTI: How Shockwave Javelin intravascular lithotripsy is opening up new frontiers in heavily calcified peripheral arterial occlusive disease
This advertorial is sponsored by Shockwave Medical. Three vascular surgeons discuss how and when they deploy the transformative Shockwave Javelin first-of-its-kind Forward Intravascular Lithotripsy (IVL) Platform in cases of heavily calcified peripheral vascular occlusive disease. Viewpoints on when and how…